Stockscreener 앱 받기
2.7908
1.23%
-0.0492
전일 마감가:
$2.84
열려 있는:
$2.87
하루 거래량:
34,312
Relative Volume:
0.63
시가총액:
$90.19M
수익:
-
순이익/손실:
$-12.48M
주가수익비율:
-7.1559
EPS:
-0.39
순현금흐름:
$-7.93M
1주 성능:
+9.14%
1개월 성능:
+6.65%
6개월 성능:
-11.79%
1년 성능:
+18.86%
1일 변동 폭
$2.79
$2.87
1주일 범위
$2.71
$3.05
52주 변동 폭
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
ANIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.80 | 84.07M | 0 | -12.48M | -7.93M | -0.39 |
|
ONC
Beone Medicines Ltd Adr
|
256.85 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.20 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2213 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.33 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
497.88 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy - Yahoo Finance
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock By Investing.com - Investing.com Canada
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock - Investing.com India
Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled - Stock Titan
Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine - marketscreener.com
Anixa Biosciences (ANIX) Concludes Enrollment for Breast Cancer Vaccine Trial | ANIX Stock News - GuruFocus
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Vaccine Achieves Major Milestone: 70% of Patients Show Promising Immune Response - Stock Titan
ANIXA BIOSCIENCES Earnings Preview: Recent $ANIX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - marketscreener.com
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Tar - GuruFocus
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Inc SEC 10-Q Report - TradingView
Anixa Biosciences (ANIX) Expected to Announce Earnings on Tuesday - Defense World
Anixa Biosciences CEO Provides Letter to Shareholders Outlining - GuruFocus
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones - Nasdaq
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual B - GuruFocus
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th - Nasdaq
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio - Finansavisen
Major Patent Win: Anixa's Revolutionary CAR-T Cancer Treatment Gains Key Protection - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting - marketscreener.com
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - marketscreener.com
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - AOL.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anixa Biosciences Inc 주식 (ANIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
| KUMAR AMIT | Chief Executive Officer |
Jan 15 '25 |
Buy |
2.23 |
43,000 |
95,890 |
559,925 |
| Catelani Michael | President, COO, & CFO |
Jan 15 '25 |
Buy |
2.15 |
9,289 |
19,971 |
44,500 |
| Titterton Lewis H jr | Director |
Oct 22 '24 |
Option Exercise |
2.58 |
16,000 |
41,200 |
912,334 |
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
1.30%
3.35%
자본화:
|
볼륨(24시간):